Balancing Payer Utilization Strategies With Clinical Effectiveness in HF
Jaime Murillo, MD, outlines payer utilization management strategies identified by the PARADIGM-HF study.
Vitiligo Diagnosis Determining Treatment Pathways
Key opinion leaders discuss how diagnosing vitiligo can lead to myriad treatment options.
Economic Burden Surrounding Vitiligo
The panel of experts address the economic burden of vitiligo from payer and provider perspectives.
Preventing CKD Underdiagnosis
Paul Sapia, MHA, acknowledges the underdiagnosis in CKD and explains how payers can incentivize screening going forward.
Screening for CKD
Dr Rajiv Agarwal explains the screening process for patients with CKD, including those who are asymptomatic.
Switching to Appropriate Guideline-Directed Therapy to Improve HF Patient Outcomes
Experts discuss improving outcomes for patients with heart failure through appropriate and timely switches to ARN inhibitors.
Pivotal Clinical Trials Shaping HF Treatment Landscape
The panel explores clinical evaluations, such as the PROVE-HF study and PARADIGM-HF trial.
Knowing the Ins and Outs of Injectable PrEP
Frank J. Palella Jr, MD, and Carl Schmid continue the discussion of patient selection for long-acting injectable PrEP and its cost effectiveness in comparison with other PrEP modalities.
Identifying the Right Patient for Injectable PrEP
Dr Lynne H. Milgram starts the conversation on choosing the right candidate for long-acting injectable PrEP, as well as how findings show it is cost effective.
Frontline Therapies for Vitiligo Treatment
Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo.
Comorbidities Associated with Vitiligo
Comorbidities and disease states associated with vitiligo are explored by a panel of key opinion leaders.
Acknowledging the Economic and Clinical Burdens of CKD and CVD
Jeffrey Feldman, MD, details the clinical burden of CKD management, and Bertram Pitt, MD, discusses the impact CKD can have on patients at risk for cardiovascular disease.
Recognizing the Economic Burden of CKD
Paul Sapia, MHA, explains the economic burden of treating chronic kidney disease.
Payer Considerations Unique to Vitiligo Treatment
David Epstein, MD, MBA, an independent consultant, gives an overview of payer considerations surrounding vitiligo.
Clinical Burden Associated with Vitiligo
Vitiligo’s effects on clinical burden and patient quality of life are addressed by Brett King, MD, PhD, and David Rosmarin, MD.
Understanding the Benefits of Multiple Options for PrEP Therapy
A clinician, advocate, and payer provide their expert knowledge on the multiple modalities of PrEP therapy and how some can be more beneficial than others.
A New Approval in the PrEP Therapeutic Landscape
Frank J. Palella, Jr discusses cabotegravir, a recently approved injectable PrEP medication, that was test in the HTPN 083 and -084 trials.
Cost of Care Driven by Early ACC Guideline-Directed Therapy in HF
Jaime Murillo, MD, shares insight on the significance of early use of American College of Cardiology treatment guidelines to manage total cost of care for patients with heart failure.
Using Population Health Strategies to Reduce Readmissions and Morbidity in HF
Rohit Uppal, MD, MBA, SFH, outlines unique treatment strategies for various ejection fraction types in the presence of comorbidities.
CKD Health Disparities and Their Consequences
Drs Feldman and Agarwal consider the health disparities commonly seen with patients that have CKD and their impact in the treatment landscape.
Unmet Needs in CKD Therapy
Paul Sapia, MHA, focuses on the gaps in care that are seen within CKD treatment.
How Biosimilar Treatment Will Change in 2023 and Beyond
Drs Kaddis and Alboustani conclude with their thoughts on contracting considerations for branded Humira in 2023, as well as what impact an interchangeable biosimilar could have in the future.
Indications for Adalimumab Biosimilar Therapy
Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products.
How to Select the Right Type of PrEP for Patients
An expert authority explains the treatment selection process for a patient, as well as the different ways to administer PrEP.
The Value of PrEP as HIV Prevention
Lynne H. Milgram, MD, MBA, CPE, iterates the importance of PrEP as an HIV prevention tactic and how walk away and fill rates are evaluated.
Recognizing Risk Factors to Mitigate Pre-Heart Failure
Dr Januzzi analyzes preventive approaches for patients with pre-heart failure, including comorbidity considerations and preliminary testing.
Prevalence of Vitiligo Across Patient Demographics
David Rosmarin, MD, discusses the prevalence and incidence of vitiligo across a diverse patient population.
Illustrating the Presentation of Vitiligo
A panel of experts open a discussion surrounding vitiligo, including the definition and nature of the disease.
Evaluating and Integrating New Data Into NSCLC Clinical Pathways
Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.
Immune Checkpoint Inhibitors in NSCLC Therapy
Dr Arrowsmith discusses the role immune checkpoint inhibitors play in NSCLC therapy, both as monotherapy and in combination therapy.
